PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29241196-9	2017	Additionally, treatment with a higher dose of calycosin significantly reduced the expression levels of Foxp3, followed by down-regulation of VEGF and MMP-9 in both MCF-7 and T47D breast cancer cells.	7,3'-dihydroxy-4'-methoxyisoflavone	46-55	vascular endothelial growth factor A	Homo sapiens	141-145	
34176787-4	2021	Molecular docking analysis indicated the binding efficacy of calycosin with three of the targets, namely TP53, AKT1, and VEGFA.	7,3'-dihydroxy-4'-methoxyisoflavone	61-70	vascular endothelial growth factor A	Homo sapiens	121-126	
34176787-6	2021	In addition, the anti-CIRI actions of calycosin were primarily through suppression of the toll-like receptor, PI3K-AKT, TNF, MAPK, and VEGF signaling pathways.	7,3'-dihydroxy-4'-methoxyisoflavone	38-47	vascular endothelial growth factor A	Homo sapiens	135-139	
31002890-7	2019	Notably, the suppressed expression of Rab27B, beta-catenin and VEGF was found in calycosin-treated MDA-MB-231 cells, accompanied with decreased invasive and migratory potential of these cells.	7,3'-dihydroxy-4'-methoxyisoflavone	81-90	vascular endothelial growth factor A	Homo sapiens	63-67	
29241196-10	2017	CONCLUSION: Treatment with a higher dose of calycosin tends to reduce migration and invasion capacity of human breast cancer cells, by targeting Foxp3-mediated VEGF and MMP-9 expression.	7,3'-dihydroxy-4'-methoxyisoflavone	44-53	vascular endothelial growth factor A	Homo sapiens	160-164